Intravesical injections of platelet‐rich plasma is effective and safe in treatment of interstitial cystitis refractory to conventional treatment—A prospective clinical trial

Aims Current treatments for interstitial cystitis/bladder pain syndrome (IC/BPS) are usually unsuccessful in achieving long‐term bladder pain relief and irritable symptom improvement. This study investigated the clinical efficacy of platelet‐rich plasma (PRP) intravesical injections on IC/BPS patients refractory to conventional therapies. Methods Forty patients received four monthly intravesical injections of 10 mL PRP extracted from 50 mL of whole blood. The primary end‐point was Global Response Assessment (GRA) at 3 months after the 4th PRP injection. Secondary endpoints included changes in O'Leary‐Sant symptom score (OSS), visual analog scale (VAS) of pain, daily frequency, nocturia, functional bladder capacity (FBC), maximum flow rate, voided volume, post‐void residual volume (PVR) from baseline to 3 months after the 4th PRP injection. Results All 40 patients (37 women and 3 men, aged 55.5 ± 11.1 years) completed the four injections and follow‐up visits. GRA improved after the 1st PRP injection and the satisfaction persists till the primary end‐point. The success rate was 45%, 52%, 70%, 70%, and 67.5% after the 1st, 2nd, 3rd, 4th, and 3 months after the 4th PRP injection, respectively. OSS and VAS also significantly decreased. The PVR did not change after repeated PRP injections, FBC increased, frequency, and nocturia were decreased after PRP injections. All patients were free of urinary tract infection or difficulty urinating. Conclusion The study demonstrated that repeated intravesical injections of autologous PRP can increase bladder capacity and provide IC symptom improvement in patients with IC/BPS refractory to conventional therapy. Autologous PRP injection is safe and effective in selected patients.